Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maralixibat in PFIC (MARCH-PFIC)
NCT03905330Phase 3Completed
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Jul 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in progressive familial intrahepatic cholestasis (PFIC) comparing Maralixibat with Placebo (2 arms). Primary endpoint: Itch Reported Outcome (Observer) Score at 26 weeks. Started Jul 2019; status: completed.
02
Drugs
maralixibat
03
Conditions
progressive familial intrahepatic cholestasis (PFIC)
Beyond the preview
Go deeper on NCT03905330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905330.